ESMO Conference Coverage
Featured Articles
(Forbes) Oct 3, 2019 - New trial suggests that doctor's shouldn't wait to add targeted therapy drugs to standard breast cancer treatment. Results from a clinical trial show that adding ribociclib, a targeted therapy drug, to the standard treatment plan for women with advanced hormone-receptor positive/HER2- breast cancer helps...
Read Article
(Northwestern Medicine) Sept 30, 2019 - Genetic-based treatment nearly doubles time without disease progression in metastatic prostate cancer. For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially...
Read Article
Latest Articles
October 10, 2019
October 08, 2019
October 03, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
October 01, 2019
View More
News Commentary
Editor Image
01 Oct, 2019 | by H. Jack West, MD
The impact of the CheckMate-227 trial remains to be seen. While it was positive...
View Comment
Editor Image
01 Oct, 2019 | by H. Jack West, MD
An important result that should satisfy the holdouts who were waiting on a...
View Comment
View More
OBR Blog
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Tari Awipi,... Read more
September 28, 2015
By: Stephanie Hawthorne, Ph.D., Senior Director, Clinical & Scientific Assessment, Kantar Health and Len Kusdra,... Read more
September 28, 2015

OBR Tweets

May 30
Pfizer Shares Fall After-Hours After Suspension Of Cancer Study #ASCO20 https://t.co/kkMwIf4371

May 30
Genentech: FDA Approves Tecentriq in Combination With Avastin for Some Liver Cancer Patients #ASCO20 https://t.co/PZv8m8CUvk

May 30
Katie Kelley, MD, of @UCSF discusses fitting tremelimumab + durvalumab into HCC treatment algorithms #ASCO20 https://t.co/PgkmKoeVoz

May 30
Nicholas Vogelzang, MD, FAC, FASCO, of @CCCNevada explains how cabazitaxel should be used in various lines of treat… https://t.co/WAkWkUFmEf

May 30
Vivek Subbiah @VivekSubbiah , MD, of @MDAndersonNews on the FDA approved product, selpercatanib, for RET-driven lu… https://t.co/ILwAZtxXfh

May 30
Final Prosper Results Show Xtandi® (Enzalutamide) Significantly Extends Overall Survival In Men With Non-Metastatic… https://t.co/BobQ15CZOj

May 30
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Nec… https://t.co/UKu93KJpLA

May 30
Vivek Subbiah @VivekSubbiah , MD, @MDAndersonNews describes solid tumor tests for RET fusion and similarities it m… https://t.co/9MlHzs422k

May 30
Saad Usmani @szusmani, MD, of @LevineCancer outlines the Phase 1 study investigating teclistamab in relapsed/refrac… https://t.co/ODs1HrnftW

May 30
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early… https://t.co/LM1kg7cgcx